Comparative Pharmacology
Head-to-head clinical analysis: MARINOL versus PROCHLORPERAZINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MARINOL versus PROCHLORPERAZINE MALEATE.
MARINOL vs PROCHLORPERAZINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronabinol is a cannabinoid receptor agonist at CB1 and CB2 receptors. It stimulates appetite and reduces nausea/vomiting via central CB1 receptor activation.
Prochlorperazine is a phenothiazine antipsychotic that primarily antagonizes dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and central nervous system. It also has anticholinergic and antiemetic effects through blockade of histamine H1 and muscarinic M1 receptors.
Dronabinol (Marinol) 2.5 mg orally twice daily, titrated to 5–20 mg daily in divided doses; max 20 mg/day. For chemotherapy-induced nausea/vomiting: 5 mg/m² orally 1–3 hours before chemotherapy, then every 2–4 hours up to 6 doses/day. For anorexia: 2.5 mg orally twice daily (before lunch and dinner).
5-10 mg orally 3-4 times daily; or 25 mg rectally twice daily; or 5-10 mg intramuscularly every 3-4 hours up to 40 mg/day; or 2.5-10 mg intravenously slowly at 2.5 mg/min, maximum 20 mg/day.
None Documented
None Documented
Dronabinol terminal half-life is 25–36 hours in adults, with a prolonged elimination phase (25–36 h) due to enteric recirculation. Chronic users may exhibit a shorter half-life due to enzyme induction.
Terminal elimination half-life is approximately 6-8 hours in adults, but may extend up to 12-15 hours after chronic dosing or in hepatic impairment.
Primarily fecal (65%) with biliary excretion; renal excretion of metabolites accounts for ~20% (mostly as glucuronide conjugates). Less than 5% of unchanged drug is excreted renally.
Primarily renal (70-80% as metabolites, <1% unchanged); fecal/biliary excretion accounts for 20-30% via enterohepatic circulation.
Category C
Category A/B
Antiemetic
Typical Antipsychotic / Antiemetic